Goldman Sachs Group Inc Vaxcyte, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 949,251 shares of PCVX stock, worth $84 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
949,251
Previous 736,739 28.84%
Holding current value
$84 Million
Previous $55.6 Million 94.81%
% of portfolio
0.02%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$70.52 - $117.12 $15 Million - $24.9 Million
212,512 Added 28.84%
949,251 $108 Million
Q2 2024

Aug 13, 2024
BUY
$60.06 - $78.77 $2.3 Million - $3.01 Million
38,247 Added 5.48%
736,739 $55.6 Million
Q1 2024

May 15, 2024
BUY
$59.79 - $81.05 $13 Million - $17.6 Million
217,373 Added 45.18%
698,492 $47.7 Million
Q4 2023

Feb 13, 2024
BUY
$45.35 - $63.41 $2.36 Million - $3.3 Million
52,005 Added 12.12%
481,119 $30.2 Million
Q3 2023

May 14, 2024
SELL
$46.0 - $53.1 $2.39 Million - $2.76 Million
-52,005 Reduced 10.81%
429,114 $21.9 Million
Q3 2023

Nov 14, 2023
SELL
$46.0 - $53.1 $769,626 - $888,416
-16,731 Reduced 3.75%
429,114 $21.9 Million
Q2 2023

May 14, 2024
SELL
$34.66 - $54.07 $1.82 Million - $2.84 Million
-52,506 Reduced 10.54%
445,845 $22.3 Million
Q2 2023

Aug 14, 2023
SELL
$34.66 - $54.07 $1.82 Million - $2.84 Million
-52,506 Reduced 10.54%
445,845 $22.3 Million
Q1 2023

May 14, 2024
BUY
$36.27 - $47.2 $3.59 Million - $4.67 Million
98,987 Added 24.79%
498,351 $18.7 Million
Q1 2023

May 11, 2023
BUY
$36.27 - $47.2 $3.59 Million - $4.67 Million
98,987 Added 24.79%
498,351 $18.7 Million
Q4 2022

May 14, 2024
SELL
$20.58 - $47.95 $1.82 Million - $4.24 Million
-88,519 Reduced 18.14%
399,364 $19.1 Million
Q4 2022

Feb 13, 2023
SELL
$20.58 - $47.95 $1.82 Million - $4.24 Million
-88,519 Reduced 18.14%
399,364 $19.1 Million
Q3 2022

May 14, 2024
BUY
$21.69 - $28.53 $2.92 Million - $3.84 Million
134,502 Added 38.06%
487,883 $11.7 Million
Q3 2022

Nov 10, 2022
BUY
$21.69 - $28.53 $2.92 Million - $3.84 Million
134,502 Added 38.06%
487,883 $11.7 Million
Q2 2022

May 14, 2024
SELL
$17.68 - $26.58 $2.26 Million - $3.4 Million
-127,738 Reduced 26.55%
353,381 $7.69 Million
Q2 2022

Aug 15, 2022
BUY
$17.68 - $26.58 $191,474 - $287,861
10,830 Added 3.16%
353,381 $7.69 Million
Q1 2022

May 16, 2022
BUY
$17.46 - $26.36 $2.52 Million - $3.8 Million
144,074 Added 72.59%
342,551 $8.27 Million
Q4 2021

Feb 14, 2022
SELL
$19.32 - $26.45 $923,824 - $1.26 Million
-47,817 Reduced 19.41%
198,477 $4.72 Million
Q3 2021

Nov 10, 2021
BUY
$20.26 - $26.97 $4.99 Million - $6.64 Million
246,294 New
246,294 $6.25 Million

Others Institutions Holding PCVX

# of Institutions
352
Shares Held
122M
Call Options Held
775K
Put Options Held
433K
View Full List

About Vaxcyte, Inc.

PCVX Quotes by TradingView
  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.25B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email